The absorption, packaging, and delivery of fat to appropriate peripheral tissues is essential for maintaining metabolic homeostasis, and defects or dysregulation of these processes can contribute to metabolic disorders such as diabetes, obesity, and hyperlipidemia. In the intestine, dietary fat is packaged into triglyceride-rich lipoprotein particles and delivered to peripheral tissues through the circulatory system. Lipolysis of lipoprotein triglycerides requires the enzyme lipoprotein lipase (LPL) and takes place on the luminal surface of capillary endothelial cells. Lipolysis by LPL is regulated in part by two proteins, GPIHBP1 and ANGPTL4. GPIHBP1, a GPI-anchored protein of capillary endothelial cells, is responsible for transporting LPL across endothelial cells to the capillary lumen. Without this transport, LPL becomes mislocalized to the interstitial space and cannot access triglyceride-rich lipoproteins, resulting in severe hypertriglyceridemia. Conversely, ANGPTL4 inhibits LPL and ANGPTL4 deficiency results in increased LPL activity and lower plasma triglyceride levels. Our goal is to understand how the interactions between LPL, GPIHBP1, and ANGPTL4 influence the delivery of triglyceride-derived fatty acids to tissues. In this thesis, I (1) use mouse models to elucidate the function of ANGPTL4 in regulating the clearance of diet-derived fat from plasma, (2) describe a mechanism for GPIHBP1-independent plasma triglyceride clearance observed in mice lacking both GPIHBP1 and ANGPTL4, and (3) propose that this GPIHBP1-independent mechanism is also operative in Gpihbp1–/– mice following a high fat diet challenge. The contributions of this thesis are significant because they close a gap in our knowledge of how and where ANGPTL4 functions, as well as indicating that, when ANGPTL4 is suppressed or absent altogether, a GPIHBP1-independent mechanism can function to clear plasma triglycerides.

L’angiogenèse, indispensable à la mise en place d’un réseau vasculaire fonctionnel, est au cœur des stratégies thérapeutiques des pathologies ischémiques. L’hypoxie, caractérisant ces tissus ischémiques, est un stimulus majeur de l’angiogenèse, en induisant l’expression de facteurs de croissance tels que le VEGF et de protéines de la matrice extracellulaire endothéliale. Nous avons identifié la protéine ANGPTL4, comme une cible majeure de l’hypoxie et ayant des effets opposés au VEGF sur la perméabilité vasculaire. Le but de cette thèse a consisté en l’analyse du rôle d’ANGPTL4 sur la formation de capillaire et l’organisation des jonctions adhérentes dans un contexte dépendant du VEGF. J’ai démontré que le VEGF stimule la formation d’un dense réseau capillaire 3D alors qu’ANGPTL4 induit la formation de capillaires étroits et peu ramifiés. ANGPTL4 réduit la taille du réseau de capillaire induit par le VEGF en limitant le nombre de bourgeons, de branchements et la largeur des capillaires. ANGPTL4 renforce l’intégrité des capillaires formés en présence de VEGF en préservant des jonctions adhérentes stables. J’ai démontré qu’ANGPTL4 limite les processus de migration 3D et de prolifération induits par le VEGF. L’analyse de la voie de signalisation VEGF/ANGPTL4 a montré une potentialisation par ANGPTL4 de la phosphorylation Y1175 du VEGFR2, impliqué dans l’internalisation de VEGFR2. En conclusion, ce modèle révèle un effet d’ANGPTL4 dépendant du contexte 3D, qui stimule les processus d’angiogenèse en absence de VEGF et qui contrecarre la morphogenèse induite par le VEGF en renforçant l’intégrité des jonctions adhérentes et en régulant la signalisation en aval du VEGFR2. / Angiogenesis, by promoting new functional capillaries, is a main target of therapeutic strategies of ischemic pathologies. Ischemic tissues are characterized by hypoxic environment, which stimulates angiogenesis by inducing expression and secretion of growth factors such as VEGF and by remodeling endothelial extracellular matrix. Our team identified ANGPTL4 as a hypoxia-induced target and characterized its counteracting effect on VEGF-induced vascular permeability. This PhD study therefore aimed to decipher the role of ANGPTL4 on angiogenesis, capillary architecture and adherens junction (VE-cadherin) organization in a VEGF-dependent context. I demonstrated that VEGF induced formation of branched capillaries forming a dense 3D network while ANGPTL4 enhanced the formation of unbranched and tight capillaries. Remarkably, ANGPTL4 reduces VEGF-induced angiogenesis, by limiting branching and widening of the capillaries. Furthermore, ANGPTL4 regulates the local VE-cadherin patterning during the sprouting process by maintaining lateral linear structures and limiting the VEGF-induced formations involved in the migratory capacities. I demonstrated that ANGPTL4 limited VEGF-induced 3D endothelial cell migration and proliferation. Analysis of VEGF/ANGPTL4 signaling pathway pointed out that ANGPTL4 enhanced phosphorylation of Y1175 VEGFR2, known to enhance internalization of VEGFR2. In conclusion, this study modeled the 3D context-dependent effect of ANGPTL4 that stimulates angiogenesis in absence of VEGF whereas it counteracts VEGF-induced endothelial morphogenesis by regulating VEGFR2 trafficking and strengthening adherens junctions.

Cardiovascular disease is a major cause of mortality and morbidity in patients on chronic haemodialysis (HD). One main contributing factor is renal dyslipidaemia, characterized by an impaired catabolism of triglyceride (TG)-rich lipoproteins with accumulation of atherogenic remnant particles. The enzyme lipoprotein lipase (LPL) is a key molecule in the lipolysis of TG-rich lipoproteins into free fatty acids. The activity of LPL is reduced in HD-patients. This study was performed to elucidate various conditions and factors that may have an impact on LPL-related lipid metabolism. I. The functional pool of LPL is located at the vascular surface. The enzyme is released by heparin and low molecular weight heparins (LMWH) into the circulating blood and extracted and degraded by the liver. Heparin and LMWH are used for anticoagulation during HD to avoid clotting in the extracorporeal devices. This raises a concern that the LPL system may become exhausted by repeated administration of LMWH in patients on HD. In a randomized cross over designed study twenty patients on chronic HD were switched from a primed infusion of heparin to a single bolus of LMWH (tinzaparin).  The LPL activity in blood was higher on HD with LMWH at 40 minutes but lower at 180 minutes compared to HD with heparin. These values did not change during the 6-month study period. With heparin a significant TG reduction was found at 40 minutes and a significantly higher TG value at 180 and 210 minutes than at start. TG was higher during the HD-session with tinzaparin than with heparin. Our data demonstrate that repeated HD with heparin or with LMWH does not exhaust the LPL-system in the long term but does disturb the LPL system and TG metabolism during every HD session. II. In this study HD patients were compared with patients on peritoneal dialysis (PD) in a case control fashion. PD patients showed the same reaction of the LPL system to LMWH as HD patients. This confirmed that both HD and PD patients had the same, reduced, heparin-releasable LPL pool. The main difference was that in PD patients the TG continued to be cleared effectively even at 180 minutes after the bolus of LMWH injection. This may be due to a slower removal of the released LPL by the liver in PD patients.  III. In recent years, citrate (Citrasate) in the dialysate has been used in Sweden as a local anticoagulant for chronic HD. We performed a randomized cross over study that included 23 patients (16 men and 7 women) to investigate if citrate in the dialysate is safe and efficient enough as anticoagulant. The study showed that citrate anticoagulation eliminated the need of heparin or LMWH as anticoagulation for HD in half of the patients. However, individual optimization of doses of anticoagulants used together with citrate have to be made. IV. Recently angiopoietin-like proteins, ANGPTL3 and 4 have emerged as important modulators of lipid metabolism as potent inhibitors of LPL. Twenty-three patients on chronic HD and 23 healthy persons were included as case and controls to investigate the levels of these proteins in plasma of HD-patients and to evaluate if HD may alter these levels. The data showed that plasma levels of ANGPTL3 and 4 were increased in patients with kidney disease compared to controls. This may lead to inactivation of LPL. High flux-HD, but not low flux-HD, reduced the levels of ANGPTL4, while the levels of ANGPTL3 were not significantly influenced.  On HD with local citrate as anticoagulant, no LPL activity was released into plasma during dialysis in contrast to the massive release of LPL with heparin (LMWH). Citrate HD was not associated with a significant drop in plasma TG at 40 minutes, while both HD with citrate and heparin resulted in significantly increased TG levels at 180 minutes compared to the start values. Conclusions:  Citrate as a local anticoagulant during haemodialysis eliminates the need of heparin or LMWH in about half of the HD patients. Citrate does not induce release of LPL from its endothelial binding sites. We have shown that although HD with heparin causes release of the endothelial pool of LPL during each dialysis session, the basal pool is similarly low in PD patients that do not receive heparin. This indicates that the LPL pool is lowered as a consequence of the uraemia, per se. One explanation could be the increased levels of ANGPTL3 and 4. HD with high flux filters can temporarily lower the levels of ANGPTL4. Further studies are, however, needed to understand why LPL activity is low in patients with kidney disease.

The ability to link a particular phenotype to its causative genotype is one of the most challenging objectives for biological research. Although the genetic code provides an explicit formula for determining the sequence of amino acid phenotypes produced by a given nucleotide sequence, identifying specific residues that are functionally important remains problematic. Many computational approaches have been developed that use patterns observed in DNA sequences to identify these critical sites. However, very few research studies have used empirical data to test whether these approaches are truly able to identify sites of interest.In most empirical studies, the actual protein function and selective pressures are unknown; thus it is difficult to assess whether computational approaches are correctly identifying critical sites. Here I present two studies that utilize well-characterized empirical systems to evaluate and compare the performance of several computational approaches. In both cases, the proteins under study have specific amino acid substitutions that are confirmed to alter protein function and expected to be constrained by natural selection. In chapter 2, I examine functional variants in angiopoietin-like protein 4 (ANGPTL4), a protein involved in regulating plasma triglyceride levels; loss-of-function variants in this gene are believed to decrease the risk of cardiovascular disease. I apply several computational approaches to identify functional variants, including phylogenetic approaches for detecting positive selection. In chapter 3, I investigate the emergence of drug-resistance in HIV-1 during the course of antiretroviral drug therapy. I compare the performance of eight selection detection methods in identifying drug-resistant mutations in 109 intrapatient datasets with HIV-1 sequences isolated at multiple timepoints throughout drug treatment.It is critical that we develop methods to detect positively selected sites. The ability to detect these sites in silico, without the need for expensive and time consuming assays, would be invaluable to researchers in evolutionary biology, human genetics, and medicine. Through the research presented in this thesis, I hope to provide insight into the strengths and weaknesses of current approaches, thereby facilitating future research towards the development and improvement of evolutionary models.

No description available.

Master of Science / Department of Animal Sciences and Industry / Barry Bradford / Angiopoietin-like protein 4 (ANGPTL4) is a 55-kDa secreted glycoprotein which is an important factor for regulation of energy and lipid metabolism. Plasma ANGPTL4 has the ability to inhibit lipoprotein lipase (LPL) function by preventing it from catalyzing hydrolysis of lipoprotein triglyceride, which contributes to ANGPTL4’s ability to decrease fat storage. Furthermore, research in mice suggests that gut microbes suppress gastrointestinal ANGPTL4 production, and that decreased plasma ANGPTL4 concentrations promote fat storage. In our previous work, we found that bovine ruminal epithelial cells expressed ANGPTL4 to a greater extent than liver hepatocytes, which are usually considered the predominant source of circulating ANGPTL4. Therefore, 3 studies were conducted to evaluate the hypothesis that ruminal expression and plasma concentrations of ANGPTL4 could be influenced by alterations in ruminal fermentation. The first and second studies utilized dietary treatments intended to alter ruminal fermentability. Diets with relatively low or high forage content were fed to 12 non-lactating dairy cows (study 1) and 8 beef cattle (study 2) prior to collection of ruminal fluid and ruminal tissue samples. The results suggested that increasing the dietary concentrate decreased ruminal expression of ANGPTL4 but did not significantly alter plasma ANGPTL4 concentrations. The third study was designed to assess whether effects of diet fermentability on ruminal ANGPTL4 synthesis are mediated by changes in volatile fatty acid concentrations. In this study, 6 lactating cows were infused with acetate, propionate, or butyrate in a Latin square design. Results showed that ANGPTL4 expression was not significantly altered by volatile fatty acid infusions, but that expression was correlated with ruminal pH and total volatile fatty acid concentration. The mechanism by which ANGPTL4 regulates intracellular lipid metabolism also remains unclear. Although ANGPTL4 is known to associate with β1 and β5 integrins, it is unknown if these extracellular matrix proteins mediate the effects of ANGPTL4 in adipose tissue or muscle. The objective of the last experiment was to detect the ANGPTL4 receptor or mediator in muscle satellite cells and adipose tissue. We successfully expressed recombinant bovine ANGPTL4 with a cell free glycoprotein synthesis system. However, we did not detect the ANGPTL4–receptor complex following exposure to bovine adipose tissue explants or cultured bovine muscle satellite cells. Overall, these research projects determined that the ruminal ANGPTL4 production is influenced by fermentation, but it remains unclear whether fermentation products or direct host/microbe interactions are responsible. Finally, it will be important to identify the ANGPTL4 receptor or mediator to better understand the downstream regulatory mechanisms involved in mediating the metabolic effects of ANGPTL4.

Das metabolische Syndrom beschreibt einen Symptomkomplex, bei welchem ein erhöhtes Körpergewicht, erhöhter Blutdruck sowie Glukose- und Fettstoffwechselstörungen gemeinsam auftreten. Insbesondere Personen mit viszeraler Adipositas sind gefährdet, atherosklerotische Erkrankungen zu entwickeln. In den letzten Jahrzehnten wurde überzeugend dargestellt, dass das vermehrte Fettgewebe bei Adipositas verschiedene Proteinhormone, sogenannte Adipokine, ausschüttet, welche metabolische und vaskuläre Komplikationen bei pathologisch erhöhtem Körpergewicht direkt beeinflussen. Im Jahr 2000 wurde fasting-induced adipose factor/angiopoietin-like protein 4 (FIAF/Angptl4) als ein neuartiges Adipokin eingeführt, welches eine wichtige Rolle im Lipid- und Glukosestoffwechsel ausübt. In der vorliegenden Studie wurde erstmals der Zusammenhang zwischen FIAF/Angptl4-Serumspiegeln und der Nierenfunktion untersucht. Rekrutiert wurden insgesamt 120 Patienten, davon 62 Männer und 58 Frauen im Alter von 32 bis 85 Jahren. Verglichen wurden 60 dialysepflichtige Patienten (CD) mit 60 Kontrollpatienten mit einer glomerulären Filtrationsrate > 50 ml/min. Die mediane Serumkonzentration des Adipokins FIAF/Angptl4 war in der Gruppe der CD-Patienten um mehr als das 5-fache höher als in der Kontrollgruppe (48,3 μg/l versus 8,4 μg/l, p<0,001). In multivariaten Regressionsanalysen war Serum-Kreatinin ein unabhängiger positiver Prädiktor für FIAF/Angptl4 in Kontrollprobanden (p=0,006). In der CD-Patientengruppe war der CRP-Wert unabhängig und positiv assoziiert mit FIAF/Angptl4 (p=0,001). Diese Ergebnisse sind vereinbar mit der Hypothese, dass FIAF/Angptl4 renal eliminiert wird. Weitere Untersuchungen sind notwendig, um eine Kausalität zwischen Niereninsuffizienz und Inflammation einerseits sowie erhöhten FIAF/Angptl4-Spiegeln andererseits nachzuweisen.:1. Bibliografische Beschreibung 2. Einführung in die Thematik 2.1 Das metabolische Syndrom als Wohlstandserkrankung 2.2 Adipokine als Verbindung zwischen Adipositas und metabolischem Syndrom 2.3 FIAF/Angptl4 als weiteres Adipokin mit potenzieller Rolle in der Pathogenese des metabolischen Syndroms 2.4 Untersuchungen im Rahmen der Dissertation 3. Publikation 4. Zusammenfassung 5. Literaturverzeichnis A. Abkürzungsverzeichnis B. Erklärung über die eigenständige Verfassung der Arbeit C. Darstellung des wissenschaftlichen Werdeganges D. Danksagung E. Nachweis über Anteile der Co-Autoren

Indiana University-Purdue University Indianapolis (IUPUI) / The incidence of Metabolic Syndrome (MetS) is increasing worldwide and accompanied by elevated risks for cardiovascular disease (CVD) and other subsequent comorbidities. MetS is associated with increased circulating triglycerides. A key enzyme involved in triglyceride (TG) clearance is lipoprotein lipase (LPL) whose activity is modulated by a variety of factors. Recent literature has identified the importance of angiopoietin-like proteins (ANGPTL) as regulators of LPL activity and has hypothesized a model in which three of these proteins interact with LPL to regulate the partitioning of TG metabolism from adipose to skeletal muscle. The work detailed in this dissertation adds to the model of ANGPTL regulation of LPL by establishing how ANGPTL8 modulates the ability of ANGPTL3 and ANGPTL4 to inhibit LPL activity in the bloodstream and localized environments, respectively. In the updated model, elevated insulin concentrations result in increased hepatic ANGPTL3/8 secretion and increased ANGPTL4/8 in adipose tissue. ANGPTL3/8 works as an endocrine molecule to inhibit skeletal muscle LPL from hydrolyzing circulating TG. Simultaneously, ANGPTL4/8 works in a paracrine mechanism to bind LPL on the endothelial vasculature adjacent to adipose tissue to alleviate ANGPTL4-mediated LPL inhibition and also prevent ANGPTL3/8 inhibition of localized LPL. Thus, in the postprandial state free fatty acids (FFA) from the hydrolysis of TG are directed into adipocytes for storage. Under fasting conditions, ANGPTL8 production is decreased in adipocytes and hepatocytes. This decreased production results in diminished ANGPTL4/8 and ANGPTL3/8 secretion from their respective tissues. As a result, ANGPTL4 inhibits adipocyte localized LPL activity while ANGPTL3 at physiological concentrations has minimal effect on LPL activity. Furthermore, any ANGPTL3/8 which is produced has its LPL-inhibitory ability diminished by the circulating apolipoprotein ApoA5. LPL is more active in skeletal muscle compared to adipose tissue where energy is shunted towards utilization in the muscle and away from storage in adipose tissue. A complete understanding of LPL regulation by ANGPTL proteins can potentially provide therapeutics targets for MetS.

Individuals with high levels of plasma triglycerides are at high risk to develop cardiovascular disease (CVD), currently one of the major causes of death worldwide. Recent epidemiological studies show that loss-of-function mutations in the APOC3 gene lower plasma triglyceride levels and reduce the incidence of coronary artery disease. The APOC3 gene encodes for apolipoprotein (APO) C3, known as an inhibitor of lipoprotein lipase (LPL) activity. Similarly, a common gain-of-function mutation in the LPL gene is associated with reduced risk for CVD. LPL is central for the metabolism of lipids in blood. The enzyme acts at the endothelial surface of the capillary bed where it hydrolyzes triglycerides in circulating triglyceride-rich lipoproteins (TRLs) and thereby allows uptake of fatty acids in adjacent tissues. LPL activity has to be rapidly modulated to adapt to the metabolic demands of different tissues. The current view is that LPL is constitutively expressed and that the rapid modulation of the enzymatic activity occurs by some different controller proteins. Angiopoietin-like protein 4 (ANGPTL4) is one of the main candidates for control of LPL activity. ANGPTL4 causes irreversible inactivation through dissociation of the active LPL dimer to inactive monomers. Other proteins that have effects on LPL activity are the APOCs which are surface components of the substrate TRLs. APOC2 is a well-known LPL co-factor, whereas APOC1 and APOC3 independently inhibit LPL activity. Given the important role of LPL for triglyceride homeostasis in blood, the aim of this thesis was to find small molecules that could increase LPL activity and serve as lead compounds in future drug discovery efforts. Another aim was to investigate the molecular mechanisms for how APOC1 and APOC3 inhibit LPL activity. Using a small molecule screening library we have identified small molecules that can protect LPL from inactivation by ANGPTL4 during incubations in vitro. Following a structure-activity relationship study we have synthesized lead compounds that more efficiently protect LPL from inactivation by ANGPTL4 in vitro and also have dramatic triglyceride-lowering properties in vivo. In a separate study we show that low concentrations of fatty acids possess the ability to prevent inactivation of LPL by ANGPTL4 under in vitro conditions. With regard to APOC1 and APOC3 we demonstrate that when bound to TRLs, these apolipoproteins prevent binding of LPL to the lipid/water interface. This results in decreased lipolysis and in an increased susceptibility of LPL to inactivation by ANGPTL4. We demonstrate that hydrophobic amino acid residues that are centrally located in the APOC3 molecule are critical for attachment of this protein to lipid emulsion particles and consequently for inhibition of LPL activity. In summary, this work has identified a lead compound that protects LPL from inactivation by ANGPTL4 in vitro and lowers triglycerides in vivo. In addition, we propose a molecular mechanism for inhibition of LPL activity by APOC1 and APOC3.

No description available.